MedTrace Logo

A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus

NCT05466643 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2024-04-08

No results posted yet for this study

Summary

A multicenter, randomized, placebo-controlled clinical trial, double-blind, parallel-group

Conditions

Interventions

DRUG

DWP16001 0.3mg

1 tablet, Orally, Once daily single dose

DRUG

DWP16001 Placebo

1 tablet, Orally, Once daily single dose

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-17
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05466643 on ClinicalTrials.gov